<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679042</url>
  </required_header>
  <id_info>
    <org_study_id>IND11807-2007-0330</org_study_id>
    <nct_id>NCT00679042</nct_id>
  </id_info>
  <brief_title>Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol</brief_title>
  <official_title>Islet Transplantation in Type 1 Diabetic Patients Using the UIC Protocol, Phase 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellTrans Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CellTrans Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In an earlier Phase 1/2 clinical trial using the Edmonton Protocol of steroid free&#xD;
      immunosuppression, investigators at University of Illinois at Chicago (UIC) demonstrated the&#xD;
      safety of islet preparation, iset transplantation, and medical treatment at UIC. Therefore,&#xD;
      the primary purpose of the present Phase 3 clinical trial is to demonstrate the safety and&#xD;
      efficacy of allogeneic islet transplantation in improving glycemic control in Type 1 diabetic&#xD;
      patients using the UIC protocol that was developed and proven effective during the Phase 1/2&#xD;
      clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 3 single center, uncontrolled trial in which 1-3 allogeneic pancreatic&#xD;
      islet transplants are performed for each study subject. Follow-up evaluations after&#xD;
      transplant continue for 52 weeks after the final islet transplantation. Thereafter, subjects&#xD;
      may enroll for a 5-year follow-up study and an additional 5 year to 10 year follow-up study&#xD;
      to evaluate the function of the islets and to measure and regulate immunosuppressive drug&#xD;
      levels and side effects.&#xD;
&#xD;
      The safety of islet transplantation depends primarily on the incidence of serious and&#xD;
      unexpected complications or adverse events and the ability of the cell isolation laboratory&#xD;
      to produce uncontaminated islet cell preparations with minimal endotoxin content.&#xD;
&#xD;
      All study subjects are followed for safety for one year. An independent Data Monitoring&#xD;
      Committee (DMC), composed of 3 members who have training in medicine and/or organ&#xD;
      transplantation, will review eligibility and safety data within 2 weeks after each islet&#xD;
      transplantation and every two months thereafter. An independent monitor, who is knowledgeable&#xD;
      about Good Clinical Practice (GCP) guidelines and regulations, monitors the study for&#xD;
      compliance with 21 CFR and according to ICH GCP Guidelines. Within the Clinical Research&#xD;
      Center, representatives of the Scientific Advisory Committee and the Research Subject&#xD;
      Advocacy Program monitor safety. These entities report to the UIC Institutional Review Board&#xD;
      (IRB), which also reviews safety data annually and on occurrence of serious adverse events.&#xD;
      The principal investigator also reports serious adverse events to the US Food and Drug&#xD;
      Administration (FDA).&#xD;
&#xD;
      Success: Islet transplantation is considered a success when subjects do not use insulin, and&#xD;
      they achieve a fasting glucose level not exceeding 140 mg/dL more than three times in a week,&#xD;
      and not exceeding two-hour post-prandial values of 180 mg/dL more than four times in a week.&#xD;
&#xD;
      Partial Success: Subjects who have a reduction in insulin requirements but who do not achieve&#xD;
      insulin independence and present with a reduction in HbA1c and number of hypoglycemic&#xD;
      episodes are considered to have partial success of islet transplantation. Reduction in&#xD;
      insulin-requirements are assessed by comparing the pre-transplant insulin requirement&#xD;
      recorded over two consecutive days (expressed as insulin units per kg) with the requirement&#xD;
      on the two consecutive days preceding the subsequent islet infusion, and the requirements on&#xD;
      two consecutive days at six months and again on two consecutive days at one year after the&#xD;
      final transplant.&#xD;
&#xD;
      Failure: Absence of measurable levels of C-peptide after transplantation is considered as&#xD;
      failure of islet cell transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 5, 2007</start_date>
  <completion_date type="Anticipated">December 19, 2023</completion_date>
  <primary_completion_date type="Actual">July 19, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>From first islet transplant through one year after last transplant (maximum 3 infusions possible), an average of 1 year</time_frame>
    <description>Safety endpoints: Incidence and severity of events related to islet infusion, immunosuppression, and islet preparations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reaching the Efficacy Goal</measure>
    <time_frame>One year after islet transplant</time_frame>
    <description>A successful primary endpoint was defined as HbA1c ≤ 6.5% at the one-year follow-up visit and absence of severe hypoglycemic events (SHE) from Day 28 post-first transplant to 1 year after first and last transplant.&#xD;
The primary analysis was to estimate the true rate of the composite favorable outcome at 1 year following first and last transplant in patients in the ITT population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Presenting With Insulin Independence at Day 365 Post First and Last Transplant</measure>
    <time_frame>1 year after islet infusion</time_frame>
    <description>Number of patients presenting with insulin independence, including:&#xD;
Absence of exogenous insulin injection reported at Day 365.&#xD;
Fasting capillary glucose level not exceeding 140 mg/dL (7.8 mmol/L) more than 3 times in a week (based on measuring capillary glucose levels a minimum of 7 times in a 7-day period) at Day 365 ± 28 days.&#xD;
Fasting plasma glucose level ≤ 126 mg/dL (7.0 mmol/L) at Day 365 ± 28 days (if the fasting plasma glucose level is &gt; 126 mg/dL [7.0 mmol/L], it must have been confirmed in an additional 1 out of 2 measurements).&#xD;
Two-hour post-prandial capillary glucose not exceeding 180 mg/dL (10.0 mmol/L) more than 1 out of every 7 times in a week (based on measuring capillary glucose levels a minimum of 7 times in a 7-day period) at Day 365 ± 28 days.&#xD;
Evidence of endogenous insulin production defined as fasting or stimulated C-peptide levels ≥ 0.5 ng/mL (0.16 nmol/L) at Day 365 ± 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic Episodes by HYPO Score</measure>
    <time_frame>One year after the last transplant</time_frame>
    <description>Hypoglycemic episodes will be measured by the Ryan hypoglycemic (HYPO) Score derived from the number and severity of hypoglycemic episodes recorded throughout the follow-up phase from Day 28 to Day 365.&#xD;
(From Ryan et al., 2004) &quot;A HYPO score was generated based on a combination of scores from the 4 weeks of readings and the patients' self-reported episodes over the previous year using the scoring system found in online appendix 2 (available at http://diabetes.diabetesjournals.org). The record sheets returned by the patients were analyzed for the number of episodes of glucose values recorded as &lt;2.5 mmol/l and between 2.5 and 2.9 mmol/l. Points were awarded if symptoms were absent or were neuroglycopenic rather than autonomic... Thus the more severe the problem with hypoglycemia, the higher the score.&quot; A Ryan score ranges from 0 (no event) to a cumulative sum of episode points of total events reported during the 4 weeks then multiplied by 13 to provide a 1-year value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Hypoglycemic Severity Measured by %Reduction in HYPO Score</measure>
    <time_frame>One year after the first and last transplant</time_frame>
    <description>%reduction in Ryan HYPO Score [%(baseline score - 1-year post transplant score)/baseline] at time of evaluation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Islets of Langerhans transplantation</intervention_name>
    <description>Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:&#xD;
Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Islets of Langerhan (Islets)</other_name>
    <other_name>Basiliximab (Simulect®)</other_name>
    <other_name>Tacrolimus (Prograf®)</other_name>
    <other_name>Sirolimus (Rapamune®)</other_name>
    <other_name>Etanercept(Enbrel®)</other_name>
    <other_name>Exenatide (Byetta®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus for more than 5 years complicated by the following situations&#xD;
             that persist despite intensive insulin management efforts:&#xD;
&#xD;
          -  At least one episode of severe hypoglycemia in the past 3 years defined as an event&#xD;
             with symptoms compatible with hypoglycemia in which the subject required the&#xD;
             assistance of another person, and which was associated with either a blood glucose&#xD;
             level &lt;50 mg/dL (2.8 mmol/L) or prompt recovery after oral carbohydrate, intravenous&#xD;
             glucose, or glucagon administration&#xD;
&#xD;
          -  Reduced awareness of hypoglycemia, defined by the absence of adequate autonomic&#xD;
             symptoms at capillary glucose levels of &lt;54 mg/dL (3 mmol/l) as reported by the&#xD;
             subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Co-existing cardiac disease: myocardial infarction within the past 6 months,&#xD;
             angiographic evidence of non-correctable coronary artery disease, ischemia on&#xD;
             functional cardiac exam, heart failure&#xD;
&#xD;
          -  Active alcohol or substance abuse, including cigarette smoking (must be abstinent for&#xD;
             six months)&#xD;
&#xD;
          -  Psychiatric disorder: schizophrenia, bipolar disorder, or major depression that is&#xD;
             unstable on medication&#xD;
&#xD;
          -  History of non-adherence to prescribed regimens&#xD;
&#xD;
          -  Active infection including hepatitis C, hepatitis B, HIV&#xD;
&#xD;
          -  TB by history, current infection, or under treatment for suspected TB&#xD;
&#xD;
          -  History of malignancies except squamous or basal skin cancer&#xD;
&#xD;
          -  Family history of MEN2 or MCT&#xD;
&#xD;
          -  Stroke within the past 6 months&#xD;
&#xD;
          -  BMI &gt;27 kg/m2&#xD;
&#xD;
          -  C-peptide response to glucagon stimulation, any C-peptide &gt;0.3 ng/mL&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Age less than 18 or greater than 75 years&#xD;
&#xD;
          -  Creatinine clearance &lt;80 mL/min/1.73 m2 by 24-hour urine collection&#xD;
&#xD;
          -  Serum creatinine consistently &gt;1.5 mg/dL&#xD;
&#xD;
          -  Macroalbuminuria &gt;300 mg/24h&#xD;
&#xD;
          -  Baseline Hb &lt;12 gm/dL in women, &lt;13 gm/dL in men&#xD;
&#xD;
          -  Baseline liver function tests outside normal range&#xD;
&#xD;
          -  Untreated proliferative retinopathy&#xD;
&#xD;
          -  Positive pregnancy test, intent for pregnancy, male's intent to procreate, unwilling&#xD;
             to use effective contraception, breast feeding&#xD;
&#xD;
          -  Previous transplant or PRA reactivity &gt;80%&#xD;
&#xD;
          -  Insulin requirement &gt;0.7 IU/kg/day&#xD;
&#xD;
          -  HbA1c &gt;12%&#xD;
&#xD;
          -  Hyperlipidemia (fasting cholesterol &gt;130 mg/dL or fasting triglycerides &gt;200 mg/dL&#xD;
&#xD;
          -  Medical condition requiring chronic use of steroids&#xD;
&#xD;
          -  Use of Coumadin or other antiplatelet or anticoagulant therapy, or PT-INR &gt;1.5&#xD;
&#xD;
          -  Factor V deficiency&#xD;
&#xD;
          -  Smoking tobacco&#xD;
&#xD;
          -  Addison's disease&#xD;
&#xD;
          -  Allergy to radiographic contrast material&#xD;
&#xD;
          -  Symptomatic cholecystolithiasis&#xD;
&#xD;
          -  Acute or chronic pancreatitis&#xD;
&#xD;
          -  Symptomatic peptic ulcer disease&#xD;
&#xD;
          -  Severe unremitting diarrhea, vomiting, or other gastrointestinal disorders that could&#xD;
             interfere with medication absorption&#xD;
&#xD;
          -  Treatment with antidiabetic medication other than insulin within 4 weeks of enrollment&#xD;
&#xD;
          -  Use of any study medication within 4 weeks of enrollment&#xD;
&#xD;
          -  Received live attenuated vaccine(s) within 2 months of enrollment&#xD;
&#xD;
          -  Any medical condition that, in the opinion of the investigator, might interfere with&#xD;
             safe participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Oberholzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.uic.edu/com/surgery/transplant/research.htm</url>
    <description>University of Illinois at Chicago Department of Surgery Homepage</description>
  </link>
  <link>
    <url>http://chicagodiabetesproject.org</url>
    <description>The Chicago Diabetes Project Homepage</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 13, 2008</study_first_submitted>
  <study_first_submitted_qc>May 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2008</study_first_posted>
  <results_first_submitted>January 24, 2021</results_first_submitted>
  <results_first_submitted_qc>March 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2021</results_first_posted>
  <disposition_first_submitted>January 22, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 22, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 24, 2019</disposition_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Jose Oberholzer</investigator_full_name>
    <investigator_title>Adjunct Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus Type 1</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>Islets of Langerhans Transplantation</keyword>
  <keyword>Allogeneic Islet transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 7, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT00679042/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT00679042/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potentially eligible patients with diabetes underwent a two-part screening phase to determine eligibility, followed by a waiting list period (as needed). The first subject consented on September 5, 2007. The last subject consented on November 4, 2014.</recruitment_details>
      <pre_assignment_details>Potentially eligible patients with diabetes were to undergo a two-part screening phase to determine eligibility, followed by a waiting list period (as needed).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.&#xD;
Islets of Langerhans transplantation: Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:&#xD;
Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Transplant + 1 Year Follow Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>5-Year Follow Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>In follow-up (ongoing)</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not consent to continue into 10-year follow up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>10-Year Follow Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>In follow-up (ongoing)</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.&#xD;
Islets of Langerhans transplantation: Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:&#xD;
Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at enrollment</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.0" lower_limit="21" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>weight</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.8" lower_limit="52.5" upper_limit="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>height</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165" lower_limit="150.9" upper_limit="181.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.4" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Emergent Adverse Events</title>
        <description>Safety endpoints: Incidence and severity of events related to islet infusion, immunosuppression, and islet preparations</description>
        <time_frame>From first islet transplant through one year after last transplant (maximum 3 infusions possible), an average of 1 year</time_frame>
        <population>Intent to treat and as treated</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.&#xD;
Islets of Langerhans transplantation: Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:&#xD;
Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Emergent Adverse Events</title>
          <description>Safety endpoints: Incidence and severity of events related to islet infusion, immunosuppression, and islet preparations</description>
          <population>Intent to treat and as treated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs rated as severe or beyond</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to death or discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reaching the Efficacy Goal</title>
        <description>A successful primary endpoint was defined as HbA1c ≤ 6.5% at the one-year follow-up visit and absence of severe hypoglycemic events (SHE) from Day 28 post-first transplant to 1 year after first and last transplant.&#xD;
The primary analysis was to estimate the true rate of the composite favorable outcome at 1 year following first and last transplant in patients in the ITT population.</description>
        <time_frame>One year after islet transplant</time_frame>
        <population>Intent to treat/as treated</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.&#xD;
Islets of Langerhans transplantation: Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:&#xD;
Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reaching the Efficacy Goal</title>
          <description>A successful primary endpoint was defined as HbA1c ≤ 6.5% at the one-year follow-up visit and absence of severe hypoglycemic events (SHE) from Day 28 post-first transplant to 1 year after first and last transplant.&#xD;
The primary analysis was to estimate the true rate of the composite favorable outcome at 1 year following first and last transplant in patients in the ITT population.</description>
          <population>Intent to treat/as treated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success at 1 yr post first transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Success at 1 yr post last transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Presenting With Insulin Independence at Day 365 Post First and Last Transplant</title>
        <description>Number of patients presenting with insulin independence, including:&#xD;
Absence of exogenous insulin injection reported at Day 365.&#xD;
Fasting capillary glucose level not exceeding 140 mg/dL (7.8 mmol/L) more than 3 times in a week (based on measuring capillary glucose levels a minimum of 7 times in a 7-day period) at Day 365 ± 28 days.&#xD;
Fasting plasma glucose level ≤ 126 mg/dL (7.0 mmol/L) at Day 365 ± 28 days (if the fasting plasma glucose level is &gt; 126 mg/dL [7.0 mmol/L], it must have been confirmed in an additional 1 out of 2 measurements).&#xD;
Two-hour post-prandial capillary glucose not exceeding 180 mg/dL (10.0 mmol/L) more than 1 out of every 7 times in a week (based on measuring capillary glucose levels a minimum of 7 times in a 7-day period) at Day 365 ± 28 days.&#xD;
Evidence of endogenous insulin production defined as fasting or stimulated C-peptide levels ≥ 0.5 ng/mL (0.16 nmol/L) at Day 365 ± 28 days</description>
        <time_frame>1 year after islet infusion</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.&#xD;
Islets of Langerhans transplantation: Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:&#xD;
Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Presenting With Insulin Independence at Day 365 Post First and Last Transplant</title>
          <description>Number of patients presenting with insulin independence, including:&#xD;
Absence of exogenous insulin injection reported at Day 365.&#xD;
Fasting capillary glucose level not exceeding 140 mg/dL (7.8 mmol/L) more than 3 times in a week (based on measuring capillary glucose levels a minimum of 7 times in a 7-day period) at Day 365 ± 28 days.&#xD;
Fasting plasma glucose level ≤ 126 mg/dL (7.0 mmol/L) at Day 365 ± 28 days (if the fasting plasma glucose level is &gt; 126 mg/dL [7.0 mmol/L], it must have been confirmed in an additional 1 out of 2 measurements).&#xD;
Two-hour post-prandial capillary glucose not exceeding 180 mg/dL (10.0 mmol/L) more than 1 out of every 7 times in a week (based on measuring capillary glucose levels a minimum of 7 times in a 7-day period) at Day 365 ± 28 days.&#xD;
Evidence of endogenous insulin production defined as fasting or stimulated C-peptide levels ≥ 0.5 ng/mL (0.16 nmol/L) at Day 365 ± 28 days</description>
          <population>Intent to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Tx Day 365 Absence of exogenous insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Tx Day 365 Absence of exogenous insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Tx Day 365 Fasting capillary glucose in a week not exceeding 140 mg/dL more than 3X</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Tx Day 365 Fasting capillary glucose in a week not exceeding 140 mg/dL more than 3X</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Tx Day 365 Fasting plasma glucose ≤126 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Tx Day 365 Fasting plasma glucose ≤126 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Tx Day 365 Post-prandial capillary glucose in a week: Not exceeding 180 mg/dL more than 1X/7X</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Tx Day 365 Post-prandial capillary glucose in a week: Not exceeding 180 mg/dL more than 1X/7X</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Tx Day 365 C-peptide (fasting or stimulated) ≥0.5 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Tx Day 365 C-peptide (fasting or stimulated) ≥0.5 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemic Episodes by HYPO Score</title>
        <description>Hypoglycemic episodes will be measured by the Ryan hypoglycemic (HYPO) Score derived from the number and severity of hypoglycemic episodes recorded throughout the follow-up phase from Day 28 to Day 365.&#xD;
(From Ryan et al., 2004) &quot;A HYPO score was generated based on a combination of scores from the 4 weeks of readings and the patients' self-reported episodes over the previous year using the scoring system found in online appendix 2 (available at http://diabetes.diabetesjournals.org). The record sheets returned by the patients were analyzed for the number of episodes of glucose values recorded as &lt;2.5 mmol/l and between 2.5 and 2.9 mmol/l. Points were awarded if symptoms were absent or were neuroglycopenic rather than autonomic... Thus the more severe the problem with hypoglycemia, the higher the score.&quot; A Ryan score ranges from 0 (no event) to a cumulative sum of episode points of total events reported during the 4 weeks then multiplied by 13 to provide a 1-year value.</description>
        <time_frame>One year after the last transplant</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.&#xD;
Islets of Langerhans transplantation: Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:&#xD;
Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemic Episodes by HYPO Score</title>
          <description>Hypoglycemic episodes will be measured by the Ryan hypoglycemic (HYPO) Score derived from the number and severity of hypoglycemic episodes recorded throughout the follow-up phase from Day 28 to Day 365.&#xD;
(From Ryan et al., 2004) &quot;A HYPO score was generated based on a combination of scores from the 4 weeks of readings and the patients' self-reported episodes over the previous year using the scoring system found in online appendix 2 (available at http://diabetes.diabetesjournals.org). The record sheets returned by the patients were analyzed for the number of episodes of glucose values recorded as &lt;2.5 mmol/l and between 2.5 and 2.9 mmol/l. Points were awarded if symptoms were absent or were neuroglycopenic rather than autonomic... Thus the more severe the problem with hypoglycemia, the higher the score.&quot; A Ryan score ranges from 0 (no event) to a cumulative sum of episode points of total events reported during the 4 weeks then multiplied by 13 to provide a 1-year value.</description>
          <population>ITT</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (pre-Tx)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266" lower_limit="2" upper_limit="1638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Tx Day 365</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" lower_limit="0" upper_limit="1234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Tx Day 365</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="0" upper_limit="1234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in Hypoglycemic Severity Measured by %Reduction in HYPO Score</title>
        <description>%reduction in Ryan HYPO Score [%(baseline score - 1-year post transplant score)/baseline] at time of evaluation.</description>
        <time_frame>One year after the first and last transplant</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.&#xD;
Islets of Langerhans transplantation: Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:&#xD;
Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Hypoglycemic Severity Measured by %Reduction in HYPO Score</title>
          <description>%reduction in Ryan HYPO Score [%(baseline score - 1-year post transplant score)/baseline] at time of evaluation.</description>
          <population>ITT</population>
          <units>percentage of HYPO baseline</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% Reduction from baseline to first tx day 365</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1" lower_limit="-300" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Reduction from baseline to last tx day 365</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1" lower_limit="-106" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first islet transplant through one year after last transplant (maximum 3 infusions possible), an average of 1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.&#xD;
Islets of Langerhans transplantation: Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:&#xD;
Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="15" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="23" subjects_affected="17" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal loss of weight</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="9" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>acne</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Cook</name_or_title>
      <organization>CellTrans Inc.</organization>
      <phone>312-413-7727</phone>
      <email>jenny@celltransinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

